Evaxion A/S (EVAX)

Market Cap	34.03M +264.0%
Revenue (ttm)	7.53M +128.6%
Net Income	-9.76M
EPS	-1.37
Shares Out	8.34M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,718
Open	4.000
Previous Close	4.060
Day's Range	4.000 - 4.250
52-Week Range	1.680 - 12.150
Beta	0.27
Analysts	Strong Buy
Price Target	11.25 (+175.74%)
Earnings Date	May 7, 2026

About EVAX

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 46
• Stock Exchange: NASDAQ
• Ticker Symbol: EVAX
• Website: https://evaxion.ai

Financial Performance

In 2025, Evaxion's revenue was $7.53 million, an increase of 125.12% compared to the previous year's $3.34 million. Losses were -$7.71 million, -27.07% less than in 2024.

Analyst Summary

According to 4 analysts, the average rating for EVAX stock is "Strong Buy." The 12-month stock price target is $11.25, which is an increase of 175.74% from the latest price.

Price Target

$11.25

(175.74% upside)

Analyst Consensus: Strong Buy